eCase Challenge: Managing a Silent Disease: Raising Awareness and Implementing Current Recommendations for the Clinical Management of Patients with Osteoporosis
This self-assessment activity outlines screening guidelines, management, and pharmacological therapy options available for patients with osteoporosis. Clinical Dialogue also available.
Member Fee: $0  Nonmember Fee: $0

Managing a Silent Disease: Raising Awareness and Implementing Current Recommendations for the Clinical Management of Patients with Osteoporosis

Lawrence Herman, MPA, PA-C, DFAAPA; Karen Cummings, PA-C; Rick Pope, MPAS, PA-C, DFAAPA, CPAAPA

Osteoporosis represents a significant healthcare problem for the aging population. Though largely considered a silent disorder, the clinical manifestations of osteoporosis place a considerable burden on the healthcare system and negatively impact patient morbidity, mortality and patient quality of life, often with lasting effects that linger for years. Although over 1.5 million osteoporosis-related fractures occur every year, a large portion of patients remain under-diagnosed and under-treated, especially among men. Less than 25% of women and 10% of men who have had an osteoporosis-related fracture are receiving pharmacologic treatment for the disease, emphasizing the need for ongoing education.

Because a fracture is often the first presenting symptom of osteoporosis, it is critical that PAs remain mindful of the prevalence and clinical severity of osteoporosis and initiate treatment to prevent these sentinel events from occurring in the first place. As there are significant risk factors for osteoporosis and a large number of patients remain undiagnosed, PAs should review all screening and diagnosis guidelines and factors that may place certain patients at a greater risk for osteoporosis development. Lastly, PAs should understand pharmacologic interventions and their benefits, limitations, usage and alternatives. Taken together, these strategies should increase the number of patients who are appropriately diagnosed and receive therapy, ultimately reducing morbidity and mortality associated with this disease.

Educational Objectives

At the conclusion of this activity, the PA should be better able to:

  • Describe the current data on osteoporosis-related morbidity, mortality and healthcare costs in the aging population.
  • Outline the screening guidelines for osteoporosis provided by the National Osteoporosis Foundation.
  • Recognize clinically significant risk factors in order to make appropriate management decisions for patients.
  • Summarize the pharmacological therapy options available for patients with osteoporosis, including their mechanisms of action, delivery method, dosage, potential adverse events and recommended duration to make individualized treatment selections.

Accreditation Statement

This activity has been reviewed and is approved for a maximum of 0.50 AAPA Category 1 Self-Assessment CME credit by the AAPA Review Panel. Participants should only claim credit commensurate with their participation in the CME activity. This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs. Approval is valid until December 31, 2017.

Responsibility Statement

AAPA takes responsibility for the content, quality, and scientific integrity of this CME activity.

Disclosure Policy Statement

It is the policy of AAPA to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational presentation. The participating faculty reported the following:

Faculty

Lawrence Herman, MPA, PA-C, DFAAPA
Moderator
Dean and Professor
College of Health Sciences
PA Studies
Gardner-Webb University
Boiling Springs, NC
No relationship with any commercial interests whose products or services may be mentioned during this presentation.

Karen Cummings, PA-C
PA Coordinator
Fragility Fracture Clinic
Associate Chief PA
Office of Clinic Affairs
University of Michigan Health System
Ann Arbor, MI
MPH Candidate - University of Michigan
No relationship with any commercial interests whose products or services may be mentioned during this presentation.

Rick Pope, MPAS, PA-C, DFAAPA, CPAAPA
Adjunct Professor
Quinnipiac University
University of Bridgeport
Western Connecticut Medical Group
Department of Rheumatology
Danbury, CT
No relationship with any commercial interests whose products or services may be mentioned during this presentation.

Activity Planners

Michael Speidel and Joanne Jeffers, Medical Logix, LLC and Judy Crespi-Lofton, MS, have no relationship with any commercial interests whose products or services may be mentioned during this presentation.

AAPA Staff Activity Planners

Daniel Pace and Jennifer Williams have no relationship with any commercial interests whose products or services may be mentioned during this presentation.

Off-Label/Unapproved Product(s) Discussion

Lawrence Herman – abaloparatide and romosozumab

Disclaimer

The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.

Acknowledgement of Commercial Support

Supported by educational funding provided by Amgen.

AAPA offers no returns or refunds for online CME activities purchased through the AAPA store. All sales are final.


Type:     Internet Activity (Enduring Material)
698 Registered Users